- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
35 result(s) found for: Orthostatic hypotension.
Displaying page 1 of 2.
EudraCT Number: 2012-002572-13 | Sponsor Protocol Number: RH-4074-OJ1 | Start Date*: 2012-09-17 | |||||||||||||||||||||||||||||||
Sponsor Name:Henrik Kehlet | |||||||||||||||||||||||||||||||||
Full Title: Efficacy of midodrine for the prevention of orthostatic hypotension during early mobilization after fast-track hip arthroplasty - a randomized, placebo controlled trial | |||||||||||||||||||||||||||||||||
Medical condition: Postoperative orthostatic hypotension during early mobilization after fast-track hip arthroplasty | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004438-18 | Sponsor Protocol Number: MeIn/06/NEB-DIA/001 | Start Date*: 2008-04-08 | |||||||||||
Sponsor Name:A. Menarini Farmaceutica Internazionale s.r.l. | |||||||||||||
Full Title: Comparative effects of Nebivolol and Carvedilol on orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus (DIANECA) | |||||||||||||
Medical condition: Orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005118-36 | Sponsor Protocol Number: NOH401 | Start Date*: 2014-06-30 | |||||||||||
Sponsor Name:Chelsea Therapeutics, Incorporated | |||||||||||||
Full Title: A clinical study of Patients with symptomatic neurogenic orthostatic HypOtENsion to assess sustaIned effects of droXidopa therapy | |||||||||||||
Medical condition: Symptomatic neurogenic orthostatic hypotension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003905-25 | Sponsor Protocol Number: HAC2018-001 | Start Date*: 2019-06-27 | |||||||||||
Sponsor Name:H.A.C. Pharma | |||||||||||||
Full Title: Evaluation of efficacy and tolerance of fludrocortisone (Flucortac) in the treatment of neurogenic orthostatic hypotension | |||||||||||||
Medical condition: Neurogenic Orthostatic Hypotension (NOH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000122-21 | Sponsor Protocol Number: SJ-193 | Start Date*: 2012-08-10 | |||||||||||
Sponsor Name:Department of Neurology, Roskilde Hospital | |||||||||||||
Full Title: Acethylcholineesterase inhibition and orthostatic hypotension in patients with parkinsons disease | |||||||||||||
Medical condition: Ortostatic hypotension in patients with Parkinsons disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005672-41 | Sponsor Protocol Number: DB001 CM 201 | Start Date*: 2007-03-30 | |||||||||||
Sponsor Name:Pierre Fabre Médicament | |||||||||||||
Full Title: Etude de l’efficacite de la dihydroergotamine par voie orale dans l’hypotension orthostatique de patients dysautonomiques | |||||||||||||
Medical condition: hypotension orthostatique d’origine neurogène chez des patients dysautonomiques | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002855-26 | Sponsor Protocol Number: Droxidopa-301 | Start Date*: 2008-10-01 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxyl... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (Pharmacodynamic, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005760-99 | Sponsor Protocol Number: SPD426-405 | Start Date*: 2013-05-30 | |||||||||||
Sponsor Name:Shire Development LLC | |||||||||||||
Full Title: A Phase 4, Randomized-withdrawal, Double-blind, Placebo controlled, Parallel-group Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects with Symptomatic ... | |||||||||||||
Medical condition: Symptomatic orthostatic hypotension (SOH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005701-22 | Sponsor Protocol Number: Droxidopa-303 | Start Date*: 2009-04-13 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A MULTI-CENTER, OPEN-LABEL STUDY, WITH A TWO WEEK RANDOMIZED, PLACEBO-CONTROLLED, WITHDRAWAL PERIOD, TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONO... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003289-15 | Sponsor Protocol Number: 0169 | Start Date*: 2019-05-08 |
Sponsor Name:Theravance Biopharma Ireland Limited | ||
Full Title: A Phase 3, 4-week, Multicenter, Randomized, Double-blind,Placebo-controlled,Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Auton... | ||
Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) EE (Completed) DE (Completed) DK (Completed) AT (Completed) HU (Completed) PL (Completed) ES (Ongoing) BG (Completed) PT (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005673-60 | Sponsor Protocol Number: Droxidopa-302 | Start Date*: 2009-04-22 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP WITHDRAWAL-DESIGN STUDY TO ASSESS THE CLINICAL EFFECT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE ... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003941-41 | Sponsor Protocol Number: 0170 | Start Date*: 2019-08-09 |
Sponsor Name:Theravance Biopharma Ireland Limited | ||
Full Title: A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) EE (Prematurely Ended) PL (Completed) ES (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) BG (Prematurely Ended) HU (Completed) PT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005761-12 | Sponsor Protocol Number: SPD426-406 | Start Date*: 2013-05-06 | |||||||||||
Sponsor Name:Shire Development LLC | |||||||||||||
Full Title: A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects with Symptomatic Orthostatic Hypo... | |||||||||||||
Medical condition: Symptomatic orthostatic hypotension (SOH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002425-30 | Sponsor Protocol Number: 0171 | Start Date*: 2020-03-17 |
Sponsor Name:Theravance Biopharma Ireland Limited | ||
Full Title: A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects... | ||
Medical condition: Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) ES (Prematurely Ended) PL (Completed) EE (Completed) FR (Completed) PT (Prematurely Ended) AT (Prematurely Ended) BG (Prematurely Ended) DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-007105-36 | Sponsor Protocol Number: Droxidopa-304 | Start Date*: 2009-06-03 |
Sponsor Name:Chelsea Therapeutics Inc. | ||
Full Title: A Multi-Centre, One Year Open-Label Study to Assess the Long-Term Safety of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-000629-38 | Sponsor Protocol Number: ACT14656 | Start Date*: 2017-07-20 | |||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Parallel Arm Dose Titration Study to Assess the Effects of SAR407899 in Patients with Microvascular Angina (MVA) and/or Persistent Stable Angina despi... | |||||||||||||
Medical condition: Microvascular coronary artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004890-24 | Sponsor Protocol Number: SNT-II-005 | Start Date*: 2008-05-07 | ||||||||||||||||
Sponsor Name:Juvantia Pharma Ltd | ||||||||||||||||||
Full Title: A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atroph... | ||||||||||||||||||
Medical condition: Neurogenic orthostatic hypotension in patients with multiple system atrophy or Parkinson's disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) PT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000122-26 | Sponsor Protocol Number: 125591 | Start Date*: 2020-05-11 | |||||||||||
Sponsor Name:University College London (UCL) | |||||||||||||
Full Title: A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and efficacy of Exenatide once-weekly in the treatment of patients with Multiple System Atrophy | |||||||||||||
Medical condition: Multiple System Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002988-10 | Sponsor Protocol Number: 1392GJK303 | Start Date*: 2012-11-19 |
Sponsor Name:Fundación para la investigacion Biomedica | ||
Full Title: Randomized, double-blind, placebo-controlled trial to compare the effect, three months of follow-on pulse pressure and vascular function of isosorbide mononitrate extended release, associated with ... | ||
Medical condition: Refractory isolated systolic hypertension | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003620-20 | Sponsor Protocol Number: P101005 | Start Date*: 2013-06-04 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Tamsulosin to prevent the failures of early bladder catheter removal after acute urinary retention in elderly women hospitalized for an acute medical problem | |||||||||||||
Medical condition: urinary disorder | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
